Surrogate Markers [qlco]
endpoints [qlco]
Surrogate End Points [qlco]
Marker [clna]
Biological [bmod]
Mechanisms [ftcn]
Mechanism [ftcn]
View [spco]
Diseases [dsyn]
Validation [resa]
Surrogate End Points [qlco]
CARDIOVASCULAR [bdsy]
Sex [orgf]
Steroids [strd]
Separate [spco]
Evaluation [ftcn]
Make [ftcn]
Various [irda]
Clinical Endpoint [clna]
Biological [bmod]
Mechanisms [ftcn]
Likely [qlco]
operate [ftcn]
Venous thromboembolic disease [patf]
arterial diseases [dsyn]
Complex [qlco]
Multifactorial [fndg]
Multiple [qnco]
Surrogate End Points [qlco]
Likely [qlco]
Relevant [qlco]
Addition [ftcn]
Sex [orgf]
Steroids [strd]
effects [qlco]
Biological [bmod]
Mechanisms [ftcn]
Validation [resa]
Available [ftcn]
Bulk [food]
Multiple [qnco]
Mechanisms [ftcn]
Large [qnco]
Addition [ftcn]
Combination [qlco]
Algorithms [inpr]
Required [ftcn]
Very [qlco]
Stage [tmco]
In [qnco]
practice [menp]
Validation [resa]
Detection [topp]
Levels [qlco]
intervention trials [resa]
End Point [qlco]
Evaluations [ftcn]
observations [resa]
Increased [qnco]
Venous [bpoc]
thromboembolic [ftcn]
Users [humn]
Sex [orgf]
Steroids [strd]
occurrence [ftcn]
Susceptible [ftcn]
subgroup [virs]
Suggest [idcn]
effects [qlco]
Group [idcn]
Dissimilar [qlco]
In [qnco]
Whole [qnco]
Ireland [geoa]
LTD [ortf]
Reserve [acty]
